Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Latest Information Update: 13 Jun 2025
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms TEZEPAIT
Most Recent Events
- 13 Jun 2025 New trial record